Tumor Immunology and Immunotherapy - Integrated Methods Part B

Lorenzo Galluzzi (Redaktør) ; Nils-Petter Rudqvist (Redaktør)

Tumor Immunology and Immunotherapy - Integrated Methods Part B, Volume 636 in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. Les mer
Vår pris
1863,-

(Innbundet) Fri frakt!
Leveringstid: Sendes innen 7 virkedager

Innbundet
Legg i
Innbundet
Legg i
Vår pris: 1863,-

(Innbundet) Fri frakt!
Leveringstid: Sendes innen 7 virkedager

Om boka

Tumor Immunology and Immunotherapy - Integrated Methods Part B, Volume 636 in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. Chapters in this update include Quantification methods of Transforming Growth Factor beta (TGF?ß) activity in the setting of cancer immunotherapy, Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses, Tracking and interrogating tissue-resident and recruited microglia in brain tumors, Metabolomics and lipidomics of the tumor microenvironment, Monitoring abscopal responses to radiation in mice, and much more.

Fakta

Innholdsfortegnelse

1. A comprehensive approach to gene expression profiling in immune cells Sabrina Carpentier, François Romagné and Eric Vivier 2. DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data Steven F. Gameiro, Farhad Ghasemi, John W. Barrett, James Koropatnick, Anthony C. Nichols, Joe S. Mymryk and Saman Maleki Vareki 3. Using epigenetic data to estimate immune composition in admixed samples Ankur Chakravarthy and Daniel De Carvalho 4. Metabolomic approaches to study the tumor microenvironment Giuseppe Astarita, Suraj Dhungana, Bindesh Shrestha and Evagelia C. Laiakis 5. Immunoscore assay for the immune classification of solid tumors: Technical aspects, improvements and clinical perspectives Florence Marliot, Lucie Lafontaine and Jérôme Galon 6. Transforming growth factor beta (TGF-ß) activity in immune-oncology studies Gabriel Gallo-Oller, Marianna Di Scala, Fernando Aranda and Javier Dotor 7. Isolation of DNA from exosomes Sheila Spada, Nils Rudqvist and Erik Wennerberg 8. Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses Shentong Fang, Patrizia Agostinis, Petri Salven and Abhishek D. Garg 9. Computational methods in tumor immunology Bhavneet Bhinder and Olivier Elemento 10. Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq Christina Plattner, Francesca Finotello and Dietmar Rieder 11. Concurrent in situ analysis of point mutations and immune infiltrate in FFPE cancers Ann-Marie Baker and Trevor A. Graham 12. RNA interference screening methods to identify proliferation determinants and mechanisms of resistance to immune attack Yong-Wei Zhang, Rochelle E. Nasto, Sandra A. Jablonski, Ilya G. Serebriiskii, Rishi Surana, Joseph Murray, Michael Johnson, Rebecca B. Riggins, Robert Clarke, Erica A. Golemis and Louis M. Weiner 13. An altered miTRAP method for miRNA affinity purification with its pros and cons Simon Jasinski-Bergner, Christoforos Vaxevanis, Nadine Heimer, Maria-Filothei Lazaridou, Michael Friedrich and Barbara Seliger 14. Identification of immunomodulatory RNA-binding proteins in tumors Michael Friedrich, Maria-Filothei Lazaridou, Jette Rahn, Christoforos Vaxevanis, Nadine Heimer, Simon Jasinski-Bergner and Barbara Seliger 15. Techniques for the generation of humanized mouse models for immuno-oncology Chun I. Yu, Florentina Marches, Te-Chia Wu, Jan Martinek and Karolina Palucka

Om forfatteren

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.

Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience. Nils-Petter Rudqvist received his M.Sc. (Physics, 2009) and Ph.D. (Medical Science, 2015) from the University of Gothenburg, Sweden. He decided to pursue an academic career and continue with his postdoctoral training in US. He first joined the Center for Radiological Research at Columbia University in New York where he studied gene signatures of radiation exposure. He then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Demaria. His current research is focused on investigating which neoantigens are key targets of the radiation-induced anti-tumor T cell response in mice and in patients treated with radiotherapy and immune checkpoint blockade. He recently demonstrated in a mouse model that radiation therapy diversifies the TCR repertoire of tumor infiltrating lymphocytes, an effect crucial for its synergy with immune checkpoint blockade treatment. Nils-Petter has also defined unique patters of expansion of TCR clonotypes in patients who respond or not to treatment with radiotherapy and ipilimumab. He has published 20 articles in peer-reviewed scientific journals and 60+ scientific conference abstracts.